• 2020 BUSINESS RESULTS APRIL 23🔍
• US FDA approves Jardiance® 🔍
• ELI LILLY AND COMPANY🔍
• Tirzepatide results published in The Lancet show ...🔍

2020 BUSINESS RESULTS APRIL 23, 2020 - Eli Lilly Investors

LOXO-305 additional data from Phase 1/2 study. POTENTIAL KEY EVENTS 2020. Not for promotional use. 2020 Q1 EARNINGS. 7. Regulatory Submissions.

US FDA approves Jardiance® (empagliflozin) to treat adults with ...

"In its phase III trials, empagliflozin has shown a statistically significant and clinically meaningful benefit in patients with heart failure ...

ELI LILLY AND COMPANY - Eli Lilly Investors

Clinical. • The company announced positive top-line results from the SURPASS-4 Phase 3 clinical trial of tirzepatide in adults with type 2 diabetes ...

Tirzepatide results published in The Lancet show ... - Eli Lilly Investors

INDIANAPOLIS, Oct. 19, 2021 /PRNewswire/ -- Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and.